N-acetylcysteine to reduce renal failure after cardiac surgery: A systematic review and meta-analysis

Canadian Journal of Anesthesia

Volumn 55, Issue 12, 2008, Pages 827-835

  Naughton, Finola ^a,b   Wijeysundera, Duminda ^a   Karkouti, Keyvan ^a   Tait, Gordon ^a   Beattie, W Scott ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; APROTININ; CREATININE; PLACEBO;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; EMBASE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART SURGERY; HUMAN; INFORMATION RETRIEVAL; KIDNEY FUNCTION; MEDLINE; META ANALYSIS; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; STROKE; SURGICAL MORTALITY; SYSTEMATIC REVIEW;

ACETYLCYSTEINE; ACUTE DISEASE; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; FREE RADICAL SCAVENGERS; HUMANS; KIDNEY FAILURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME;

EID: 57349123544     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03034054     Document Type: Review

References (56)

1. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998; 104: 343-8.
2. Conlon PJ, Stafford-Smith M, White WD, et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant 1999; 14: 1158-62.
3. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1: 19-32.
4. Zanardo G, Michielon P, Paccagnella A, et al. Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors. J Thorac Cardiovasc Surg 1994; 107: 1489-95.
5. Abel RM, Buckley MJ, Austen WG, Barnett GO, Beck CH Jr, Fischer JE. Etiology, incidence, and prognosis of renal failure following cardiac operations. Results of a prospective analysis of 500 consecutive patients. J Thorac Cardiovasc Surg 1976; 71: 323-33.
6. Andersson LG, Ekroth R, Bratteby LE, Hallhagen S, Wesslen O. Acute renal failure after coronary surgery - a study of incidence and risk factors in 2009 consecutive patients. Thorac Cardiovasc Surg 1993; 41: 237-41.
7. Antunes PE, Prieto D, Ferrao de Oliveira J, Antunes MJ. Renal dysfunction after myocardial revascularization. Eur J Cardiothorac Surg 2004; 25: 597-604.
8. Corwin HL, Sprague SM, DeLaria GA, Norusis MJ. Acute renal failure associated with cardiac operations. A case-control study. J Thorac Cardiovasc Surg 1989; 98: 1107-12.
9. Del Duca D, Iqbal S, Rahme E, Goldberg P, de Varennes B. Renal failure after cardiac surgery: timing of cardiac catheterization and other perioperative risk factors. Ann Thorac Surg 2007; 84: 1264-71.
10. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative ischemia Research Group. Ann Intern Med 1998; 128: 194-203.
11. Mangos GJ, Brown MA, Chan WY, Horton D, Trew P, Whitworth JA. Acute renal failure following cardiac surgery: incidence, outcomes and risk factors. Aust N Z J Med 1995; 25: 284-9.
12. Stallwood MI, Grayson AD, Mills K, Scawn ND. Acute renal failure in coronary artery bypass surgery: independent effect of cardiopulmonary bypass. Ann Thorac Surg 2004; 77: 968-72.
13. Chukwuemeka A, Weisel A, Maganti M, et al. Renal dysfunction in high-risk patients after on-pump and off-pump coronary artery bypass surgery: a propensity score analysis. Ann Thorac Surg 2005; 80: 2148-53.
14. Grayson AD, Khater M, Jackson M, Fox MA. Valvular heart operation is an independent risk factor for acute renal failure. Ann Thorac Surg 2003; 75: 1829-35.
15. Kulka PJ, Tryba M, Zenz M. Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Crit Care Med 1996; 24: 947-52.
16. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139-43.
17. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510-24.
18. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-91.
19. Bove T, Landoni G, Calabro MG, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 2005; 111: 3230-5.
20. Landoni G, Biondi-Zoccai GG, Marino G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2008; 22: 27-33.
21. Cogliati AA, Vellutini R, Nardini A, et al. Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: a randomized clinical study. J Cardiothorac Vasc Anesth 2007; 21: 847-50.
22. Ranucci M, Soro G, Barzaghi N, et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg 2004; 78: 1332-7; discussion 1337-8.
23. Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 2000; 11: 97-104.
24. Vargas Hein O, Staegemann M, Wagner D, et al. Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. Ren Fail 2005; 27: 385-92.
25. Lombardi R, Ferreiro A, Servetto C. Renal function after cardiac surgery: adverse effect of furosemide. Ren Fail 2003; 25: 775-86.
26. Hummel M, Kuhn M, Bub A, et al. Urodilatin, a new therapy to prevent kidney failure after heart transplantation. J Heart Lung Transplant 1993; 12: 209-17; discussion 217-8.
27. Brenner P, Meyer M, Reichenspurner H, et al. Significance of prophylactic urodilatin (INN: ularitide) infusion for the prevention of acute renal failure in patients after heart transplantation. Eur J Med Res 1995; 1: 137-43.
28. Amano J, Suzuki A, Sunamori M, Tofukuji M. Effect of calcium antagonist diltiazem on renal function in open heart surgery. Chest 1995; 107: 1260-5.
29. Bergman AS, Odar-Cederlof I, Westman L, Bjellerup P, Hoglund P, Ohqvist G. Diltiazem infusion for renal protection in cardiac surgical patients with preexisting renal dysfunction. J Cardiothorac Vasc Anesth 2002; 16: 294-9.
30. Kawamura T, Nara N, Kadosaki M, Inada K, Endo S. Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery. Crit Care Med 2000; 28: 2201-8.
31. Morgera S, Woydt R, Kern H, et al. Low-dose prostacyclin preserves renal function in high-risk patients after coronary bypass surgery. Crit Care Med 2002; 30: 107-12.
32. Gouyon JB, Guignard JP. Theophylline prevents the hypoxemia-induced renal hemodynamic changes in rabbits. Kidney Int 1988; 33: 1078-83.
33. Katholi RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995; 195: 17-22.
34. Kramer BK, Preuner J, Ebenburger A, et al. Lack of renoprotective effect of theophylline during aortocoronary bypass surgery. Nephrol Dial Transplant 2002; 17: 910-5.
35. Bronicki RA, Backer CL, Baden HP, Mavroudis C, Crawford SE, Green TP. Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2000; 69: 1490-5.
36. Loef BG, Henning RH, Epema AH, et al. Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass. Br J Anaesth 2004; 93: 793-8.
37. Morariu AM, Loef BG, Aarts LP, et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest 2005; 128: 2677-87.
38. Mandke A, Mevada H, Borkar S, Mandke N. Clinical efficacy of clonidine as an adjunct to anaesthesia for coronary artery bypass graft surgery. Ann Card Anaesth 1999; 2: 22-7.
39. Kaya K, Oguz M, Akar AR, et al. The effect of sodium nitroprusside infusion on renal function during reperfusion period in patients undergoing coronary artery bypass grafting: a prospective randomized clinical trial. Eur J Cardiothorac Surg 2007; 31: 290-7.
40. Burns KE, Chu MW, Novick RJ, et al. Perioperative N-acetylcysteine to prevent renal dysfunction in highrisk patients undergoing CABG surgery: a randomized controlled trial. JAMA 2005; 294: 342-50.
41. Ristikankare A, Kuitunen T, Kuitunen A, et al. Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. Br J Anaesth 2006; 97: 611-6.
42. El-Hamamsy I, Stevens LM, Carrier M, et al. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2007; 133: 7-12.
43. Haase M, Haase-Fielitz A, Bagshaw SM, et al. Phase ii, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med 2007; 35: 1324-31.
44. Wijeysundera DN, Beattie WS, Rao V, Granton JT, Chan CT. N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. Can J Anesth 2007; 54: 872-81.
45. Sisillo E, Ceriani R, Bortone F, et al. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. Crit Care Med 2008; 36: 81-6.
46. Moss M, Wellman DA, Cotsonis GA. An appraisal of multivariable logistic models in the pulmonary and critical care literature. Chest 2003; 123: 923-8.
47. Barr LF, Kolodner K. N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery. Crit Care Med 2008; 36: 1427-35.
48. Wijeysundera DN, Rao V, Beattie WS, Ivanov J, Karkouti K. Evaluating surrogate measures of renal dysfunction after cardiac surgery. Anesth Analg 2003; 96: 1265-73.
49. Charlson ME, MacKenzie CR, Gold JP, Shires GT. Postoperative changes in serum creatinine. When do they occur and how much is important? Ann Surg 1989; 209: 328-33.
50. Wijeysundera DN, Karkouti K, Dupuis JY, et al. Derivation and validation of a simplified predictive index for renal replacement therapy after cardiac surgery. JAMA 2007; 297: 1801-9.
51. Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, Trovati M. N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets. Eur J Clin Invest 2001; 31: 452-61.
52. Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985; 76: 703-8.
53. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65.
54. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297: 471-9.
55. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 2006; 46: 327-38.
56. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801-13.